Table 1.

Comparison of Demographics and Severe Illness State at Initial Acute Myeloid Leukemia Presentation Between Those Receiving and Those Not Receiving Antifungal Prophylaxis

Characteristic	All Patients (N = 871)		No Prophylaxis (n = 376)		Prophylaxis (n = 495)		P Value
	No.	%	No.	%	No.	%
Age at start of chemotherapy							.72
<1 y	89	10.2	40	10.6	49	9.9
1 to <3 y	170	19.5	76	20.2	94	19.0
3 to <10 y	198	22.7	77	20.5	121	24.4
10 to <15 y	249	28.6	108	28.7	141	28.5
15 to <19 y	165	18.9	75	20.0	90	18.2
Sex							.16
Male	465	53.4	211	56.1	254	51.3
Female	406	46.6	165	43.9	241	48.7
Race							.83
White	603	69.2	258	68.6	345	69.7
Black	114	13.1	51	13.6	63	12.7
Asian/Pacific Islander	33	3.8	16	4.3	17	3.4
Native American	7	0.8	4	1.1	3	0.6
Other	82	9.4	36	9.6	46	9.3
Unknown	32	3.7	11	2.9	21	4.2
Insurance at start of chemotherapy							.33
Private	318	36.5	150	39.9	168	33.9
Government	365	41.9	150	39.9	215	43.4
Self-pay	18	2.1	8	2.1	10	2.0
Other	170	19.5	18	18.1	102	20.6
Severely ill at time of AML presentation							.007
Yes	41	4.7	26	6.9	15	3.0
No	830	95.3	350	93.1	480	97.0

Abbreviation: AML, acute myeloid leukemia.